Risk Factors for the Development of Left Ventricular Hypertrophy in a Prospectively Followed Cohort of Dialysis

Size: px
Start display at page:

Download "Risk Factors for the Development of Left Ventricular Hypertrophy in a Prospectively Followed Cohort of Dialysis"

Transcription

1 Risk Factors for the Development of Left Ventricular Hypertrophy in a rospectively Followed Cohort of Dialysis I John D. Harnett2, Gloria M. Kent, aul E. Bane, Rhoda Taylor, and atrick S. arfrey J.D. Harnett, G.M. Kent,.S. arfrey, The Division of Nephrology, The Health Sciences Centre, Memorial University of Newfoundland, St. John s, Newfoundland, Canada.E. Barre, I?. Taylor, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada (J. Am. Soc. Nephrol. 1994; 4: ) ABSTRACT The objective of this study was to determine the role of hypertension, age, anemia, and hyperparathyroidism in the pathogenesis of left ventricular hypertrophy (LVH) developing after the initiation of dialysis for ESRD. A cohort of dialysis patients who were being treated for ESRD and whose initial echocardiograms after the start of dialysis therapy do not show LVH were studied. Three hundred and thirty-nine patients have been monitored at three centers since Serial echocardiograms have been performed with M-mode and two-dimensional echocardiography. Data on blood pressure, height, weight, hemoglobin, number and type of antihypertensive medications, and the presence of functioning vascular access have been collected prospectively. rospective data on serum calcium, serum phosphorus, alkaline phosphatase, and parathyroid hormone levels and skeletal x-rays have also been collected. By the use of set criteria and blinding to echocardiographic outcome, the presence and severity of hyperparathyroidism were graded by consensus. Fifty-one patients met eligibility criteria for inclusion; of these, 14 developed LVH (cases) and 37 did not (controls). had significantly higher systolic blood piessure ( = 0.009) and were older ( = 0.01) than controls. Systolic blood pressure correlated signifi- cantly with final posterior left ventricular wall thickness (r = 0.39; < 0.0 1). By the use of multivariate analysis, age and systolic blood pressure were significantly and independently associated with increased left ventricular mass index. The frequency of hyperparathyroidism was low and equal in both groups. There was a trend toward more severe anemia in cases that did not reach statistical significance. IVH developing after the initiation of dialysis for ESRD is associated with increased systolic blood pressure and older age. Key Words: Dialysis, left ventricular hypertrophy, risk factors L eft ventricular hypertrophy (LVH) is very common in patients with ESRD treated by dialysis, occurring in 68% of our nondiabetic dialysis patients (1). In patients without ESRD. electrocardiographicalby detected LVH is associated with a 5-yr mortality of 30% (2). Echocardiographically detected LVH is also associated with increased morbidity and mortality (3). Dialysis patients with LVH have an increased incidence of coronary events, stroke, and death when monitored prospectively (4,5). Among patients without ESRD, risk factors for LVH include increased body mass index, hypertension, gender, age, and diabetes mellitus (6). atients with ESRD have many additional potential risk factors for LVH including anemia (7). functioning vascubar access (8), hyperparathyroldism (9). aluminum accumulation ( 1 0). and perhaps an excess of NA-K- ATase inhibitors (1 1). In uremic subjects, the correlation between blood pressure and cardiac mass has not been impressive (1,12). In this study. we have prospectively monitored a cohort of dialysis patients initially free of LVH to answer the following question. Do nondiabetic dialysis patients who develop LVH differ from dialysis patients without LVH with respect to severity of hypertenslon, type of antihypertensive medication used, age, degree of anemia, and the presence and severity of hyperparathyroidism? I Received December Accepted April 1, Correspondence to Dr. J.D. Harnett, DIvialon of Nephrology. The Health sd- CncC$ Centre, rince hllllp Drive. St. John s, Newfoundland, AIB 3V6, Canada / $03.00/0 Journal of the American Society of Nephroloqy Copyright C 1994 by the American Society of Nephrology METHODS All dialysis patients at the Health Sciences Centre and the Grace General Hospital. St. John s, and the 1486 Volume 4. Number 7 #{149}1994

2 Harnett et al Royal Victoria Hospital, Montreal, have had annual echocardiography since and prospective measurements of several relevant risk factors. atients were eligible for inclusion in this study if they: (1) had been on dialysis for at least 2 yr or had at least two routine echocardiograms; (2) were free of diabetes mellitus; or (3) had no echocardiographic evidence of LVH (posterior left ventricular wall thickness (LVWT] 1.2 cm) at the start of dialysis. atients were monitored prospectively, and those patients whose LVWT increased to 1.2 cm or more and whose LVWT increased by at least 0.2 cm were designated as cases. The remaining eligible patients formed the control group. Exposure data were collected prospectively on each patient blind to the final echocardiographic diagnosis. Blood pressure was measured routinely and documented in both hemodialysis and peritoneal dialysis continuous ambulatory peritoneal dialysis patients. For hemodialysis patients, mean predialysis blood pressure values were used, and monthly blood pressure values were documented in continuous ambulatory peritoneal dialysis patients. arterial pressures were calculated for all patients. Readings were recorded from the time of the initiation of dialysis therapy until the most recent echocardiogram. The number and type of antihypertensive medications used were recorded, and antihypertensive drugs were categorized as /3-blockers, vasodilators, angiotensin-converting enzyme inhibitors, centrally acting agents, calcium channel blockers, and others. Serial data on serum calcium, serum phosphorus, alkaline phosphatase, and parathyroid hormone (TH) levels and annual skeletal x-rays were recorded. These data were then reviewed by two nephrobogists (J.D. Harnett and.s. arfrey) blind to the echocardiographic diagnosis. Hyperparathyroidism was graded. by the use of set criteria, as absent, mild, or severe. Severe hyperparathyroidism was said to be present if the TH level was elevated and if skeletal x-rays showed definite changes of hyperparathyroidism. Mild disease was diagnosed if TH 1evels were elevated in association with raised alkaline phosphatase bevels and minimal or absent x-ray changes. Hyperparathyroidism was said to be absent if skeletal x-rays were normal and serum calcium and alkaline phosphatase levels were within the normal range; TH bevels could be normal or elevated. In reaching a diagnosis, therapy with 1.25 vitamin D and calcium supplements was taken into account in the interpretation of the laboratory values. All patients had age. sex, height, weight, body surface area, duration of dialysis therapy. and the type of underlying renal disease documented. In addition, monthly hemoglobin measurements were recorded. M-mode echocardiography was performed by cxperienced echocardiographers. in routine clinical conditions, using the criteria set forth by the American Society of Echocardiographers ( 1 3). Echocardiograms were usually performed within 24 h after a dialysis session in hemodialysis patients. Echocardiograms in both hemodialysis and peritoneal dialysis patients were performed at a time when they were felt to be close to dry weight. All data were entered on computer mainframe with Datatrieve software and were analyzed on the SSSX and BMD statistical software packages. Categorical variables were analyzed by the use of x2 tests or Fisher s exact test. Continuous variables were analyzed by use of the t test for unpaired variables. Multivariate analysis was performed by the use of multiple linear regression. A two-tailed value of 0.05 or less was considered significant. RESULTS Three hundred thirty-nine patients were reviewed for entry into the study. Forty-four were excluded because of diabetes, 1 65 were excluded because of abnormal echocardiography. 29 were excluded because transplantation occurred before a second echocardiogram, 1 1 died before a second echocardiogram, and 39 had incomplete echocardiographic measurements because of technical problems. Fiftyone nondiabetic patients with initially normal left ventricular (LV) wall thickness were entered into the study. The mean duration of follow-up was 29 mo (, 20). Fourteen subjects developed LVH (cases), and 37 patients did not (controls). Table 1 lists the demographic characteristics and echocardiographic measurements of both groups at baseline. Those patients who developed LVH were significantly older than TABLE I. Baseline demographic and echocardiographic data in case and control patients Cas es - Cont Age(yr) LVWTinDiastole (mm) IV End-Diastolic Diam eter (mm) IV Mass Index (g/m2) IeftAtrium(mm) DurationofFollow-Up MaIe,N(%) Hemodialysis, N(%) I I rols Journal of the American Society of Nephrology 1487

3 Risk Factors for the Development of LVH those who did not, and the duration of follow-up was longer. Initial echocardiographic parameters were very similar in both groups. LVWT increased from a baseline value of 10.4 mm to a final value of 13.8 mm in cases, and their LV mass index increased from to g/m2. LVWT and LV mass did not change in control subjects (Tables 1 and 2). Because of differences in the duration of followup, we booked at echocardiographic parameters in both groups after approximately 1 8 mo of follow-up. These data are presented in Table 3 and demonstrate that LVWT was already significantly higher in cases than in controls at that time. had significantly higher systolic blood pressure than did controls ( [, 1 3.4] versus (. 15.7] mm Hg; = There were no statistically significant differences between cases and controls In diastolic blood pressure, mean arterial blood pressure, mean mnterdialytic weight gain, number of antihypertensive medications taken, and mean hemogbobin bevel (Table 4). Systolic blood pressure and final LVWT were significantly correlated (r = 0.39; < 0.01) (Figure 1). When hemodialysis and peritoneal dialysis patients were examined separately. similar findings were seen in both groups (Table 5). In peritoneal dialysis patients. the same trends, apart from increased age in cases. were present, but statistical significance was lacking because of the small sample size. There were no differences in the type of antihypertensive medications taken, although there was a trend toward a higher prevalence of centrally acting agents in the cases (Table 6). TABLE 4. Blood pressure and hemoglobin levels in cases and controls 0 B. blood pressure. b Hemodlalysis patients only. 18 I- r=0.39.!- E #{176} - 14 C a).. >81.. #{149}. 1-.C a (N = 14) (N 37) SystolicB(mmHg) Arterial ressure I (mm Hg) Diastolic B (mm Hg) Hemoglobin(g/I) Interdialytic Weight I Gain (kg)b Systolic Blood ressure (mmhg) Figure 1. Systolic blood pressure and final LVWT were significantly correlated (< 0.01). 180 p TABLE 2. Indices of LVH at last follow-up IVWT(mm) <0.001 IVMasslndex(g/ m2) Increase in LVWT <0.001 (mm) TABLE 3. LVWT in cases and controls at uniform follow-up time Cas es Cont IVWT(mm) DurationofFollow-Up rols Severe or mild hyperparathyroidism occurred in a minority of patients in both groups. and the proportion did not differ significantly between cases and controls (Table 6). Only one patient in each group was categorized as having severe hyperparathyroidism. The proportion of patients with functioning vascular access was similar in both groups. However, flow rate measurements were not available. Three of 1 4 cases were receiving erythropoietmn during the course of the study compared with 5 of 37 controls ( = 0.38; Fisher s exact test). Multiple linear regression used final LV mass as the dependent variable and systolic blood pressure, duration of follow-up, hyperparathyroidism, type of dialysis treatment, age. and hemoglobin levels as independent variables. Age ( = 0.03) and mean systolic blood pressure ( = 0.05) were the only variables independently and significantly associated with increased LV mass. The regression equation is presented in Table Volume 4 Number

4 Harnett et al TABLE 5. Risk factors for IVH in different dialysis modalities Hemodialysis eritonea I Dialysis (N= 11) (N= 23) (N= 3) (N= 14) Age(yr) SystolicBloodressure (mm Hg) Hemoglobin(g/I) DurationofFollow-Up TABLE 6. arathyroid status and type of antihypertensive medications in case and control subjects N % N % Hyperparathyroidism Severeormild Absent Antihypertensive Treatment Ca channel blocker blocker Angiotensin-converting enzyme inhibitor Vasodilator Centrally active a Fisher s exact test when N< 5; x2 when N> 5. TABLE 7. Multiple linear regression equation IVMass=2+7.6Tx+2.2Har+ 1.l2age FU sbp mhgb. where Tx = type of dialysis Har = hyperparathyroidism FU = duration of follow-up sbp = Systolic blood pressure mhgb = mean hemoglobin level DISCUSSION This study clearly establishes a relationship between systolic arterial hypertension and the devebopment of LVH in dialysis patients. In our previous study ( 1 ). there were a number of reasons why such an association may not have been found. The majority of patients already had LVH at the time of starting dialysis and predialysis blood pressures were not assessed. Cross-sectional blood pressure data might also be less accurate in predicting LVH than prospectively accumulated data. Although the relationship between systolic hypertension and LVH is clear in nonuremic individuals (6), this study is, to our knowledge, the first to clearly establish such a relationship among patients with ESRD. who developed LVH were significantly older than controls at baseline but nevertheless had virtually identical initial echocardiographic measurements. Our analysis shows that both age and systolic blood pressure were independent predictors of the development of LVH. Other authors have demonstrated an increased frequency of LVH with increasing age in nonuremic subjects (14-16). Our previous study in dialysis patients showed an association between age and severe LVH (1). It may be that the aging ventricle is more sensitive to the hypertrophic stimulus of an elevated systolic blood pressure. There was a tendency toward more severe anemia in the group who developed LVH that did not reach statistical significance. Given our sample size, however, we are unwilling to exclude an association between anemia and the development of LVH in dialysis patients on the basis of these data. were monitored for a significantly longer period than control subjects. However, LVH had already developed by 1 8 mo in the majority of cases. The duration of follow-up was entered as an independent variable in the multivariate analysis and did not emerge as being independently predictive of the development of LVH. Therefore, although the duration of follow-up is different in both groups. we do not believe that this affects our conclusions. Hyperparathyroidism was not common and does not appear in this study to be an important predictor of the development of LVH after the initiation of dialysis. Its robe in patients who already have LVH at the start of dialysis was not assessed by this study and remains controversial. It should be noted that our data only apply to those dialysis patients who developed LVH after dialysis Journal of the American Society of Nephrology 1489

5 Risk Factors for the Development of LVH has been initiated. This represents only a minority of prevalent cases of LVH in dialysis patients. Thus, these data should be generalized only to LVH developing in patients already on dialysis. In conclusion, our study shows that age and elevated systolic blood pressure are associated with the development of LVH after the initiation of dialysis. Hyperparathyroidism does not have major etiobogic Importance in the development of LVH in this group of patients. Although we cannot exclude an effect of anemia, hemoglobin differences were not major. We suggest that careful control of blood pressure levels in dialysis patients may have an important role in preventing the development of LVH. ACKNOWLEDGMENTS Supported by a grant from the Kidney Foundation of Canada. Dr. J.D. Harnett held a scholarship from the Kidney Foundation of Canada. REFERENCES 1. Harnett JD, arfrey S, Griffiths SM, Gault MB, Barre E, Guttman D: Left ventricular hypertrophy in endstage renal disease. Nephron 1988; 48: Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram: revalence, incidence and mortality in the Framingham Study. Ann Intern Med 1969;71: Levy D, Garrison RJ, Savage DD, Castelli WD: rognostic implications of echocardiographically determined left ventricular mass in the Framinham Heart Study. N Engl J Med 1990;322: arfrey S, Harnett JD, Griffiths SM, et at.: The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990;55: Silberberg JS, Barre, richard S, Sniderman AD: Left ventricular hypertrophy: An independent determinant of survival in endstage renal failure. Kidney Int 1989;36: Hammond IN, Devereux RB, Alderman MB, et at. : The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986;7: Neff MS, Kim KE, ersoff M, et at.: Hemodynamics of uremic anemia. Circulation ;43: Anderson CB, Lodd JR, Graff RA, Grace MA, Harter MR. Newton WT: Cardiac failure and upper extremity arterlovenous dialysis fistula. Arch Intern Med 1 976;3: London GM, de Vernejoul MC, Fabiani F, et at.: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1 987;32: London GM, de Vernejoul MC, Fabiani F, et at.: Association between aluminum accumulation and cardiac hypertrophy in hemodialyzed patients. Am J Kidney Dis 1989;8: Schreiber V, Korbel F: Does an endogenous digitalis-like immunoreactive factor participate in the development of cardiomegaly. Cor Vasa 1 982;24: London GM, Fabiarn F, Mardrais SJ, et at.: Uremic cardiomyopathy: An inadequate left yentricular hypertrophy. Kidney mt i 987;3 1: Sahn DJ, De Maria A, Kisslo J: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1 978; 58: Gardin JM, Henry WL, Savage DD, Epstein SE: Echocardiographic evaluation of an older population without clinically apparent heart disease [Abstractj. Am J Cardiol 1977;39: Gerstenblith G, Frederiksen J, Yin FC, Fortin NJ, Lakatta EG, Weisfeldt ML: Echocardiographic assessment of a normal aging population. Circulation 1 977;56: Marcomichelakis J, Withers R, Newman GB, O Brien K, Emmanuel R: The relation of age to the thickness of the interventricular septum, the posterior left ventricular wall and their ratio. Int J Cardiol 1983;4: Volume 4 - Number

LEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS

LEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS Peritoneal Dialysis International, Vol. 20, pp. 461 466 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis LEFT VENTRICULAR HYPERTROPHY

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

Dr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA.

Dr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA. Original Article In hypertensive patients measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular

More information

Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods

Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods DIALYSIS Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods Amir Ahamd Nassiri, 1 Legha Lotfollahi, 2,3 Neda Behzadnia, 4 Ilad Alavi Darazam,

More information

Prevalence of cardiovascular damage in early renal disease

Prevalence of cardiovascular damage in early renal disease Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

Prevalence of left ventricular hypertrophy in a hypertensive population

Prevalence of left ventricular hypertrophy in a hypertensive population European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.

More information

Echocardiography analysis in renal transplant recipients

Echocardiography analysis in renal transplant recipients Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical

More information

Mareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki Ohtsuka, Hidetoshi Shuntaro Ikeda, Makoto Suzuki, Yuji Hara, and Kunio Hiwada

Mareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki Ohtsuka, Hidetoshi Shuntaro Ikeda, Makoto Suzuki, Yuji Hara, and Kunio Hiwada 297 Original Article Serum Creatinine Level Renal Involvement Essential Underestimates Hypertensive in Elderly Patients with Hypertension Yuji Shigematsu, Mareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki

More information

Left ventricular mass in offspring of hypertensive parents: does it predict the future?

Left ventricular mass in offspring of hypertensive parents: does it predict the future? ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Left ventricular mass in offspring of hypertensive parents: does it predict the future? P Jaiswal, S Mahajan, S Diwan, S Acharya,

More information

Aortic stenosis (AS) is common with the aging population.

Aortic stenosis (AS) is common with the aging population. New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting

More information

Noor Naif Al-Hakami. Pharm-D candidate (KSU)

Noor Naif Al-Hakami. Pharm-D candidate (KSU) Hypertension In Hemodialysis Patients Treated With Atenolol Or Lisinopril: A Randomized Controlled Trial (Rajiv Agarwal, Arjun D. Sinha, Maria K. Pappas, Terri N. Abraham and Getachew G. Tegegne ) Noor

More information

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais

More information

Long-term evolution of cardiomyopathy in dialysis patients

Long-term evolution of cardiomyopathy in dialysis patients Kidney International, Vol. 54 (1998), pp. 1720 1725 Long-term evolution of cardiomyopathy in dialysis patients ROBERT N. FOLEY, PATRICK S. PARFREY, GLORIA M. KENT, JOHN D. HARNETT, DAVID C. MURRAY, and

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For

More information

Journal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.

Journal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30. Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00052-4

More information

The Prognostic Importance of Left Ventricular Geometry in Uremic Cardiomyopathy1. mortality in dialysis patients, their prognostic effects

The Prognostic Importance of Left Ventricular Geometry in Uremic Cardiomyopathy1. mortality in dialysis patients, their prognostic effects The Prognostic Importance of Left Ventricular Geometry in Uremic Cardiomyopathy1 Robert N. Foley,2 Patrick S. Parfrey, John D. Harnett, Gloria M. Kent, David C. Murray, and Paul E. Barr#{233} RN. Foley.

More information

PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY

PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 22 (28-33) ORIGINAL ARTICLE PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Internet Journal of Medical Update, Vol. 3, No. 2, Jul-Dec 2008

Internet Journal of Medical Update, Vol. 3, No. 2, Jul-Dec 2008 Evaluation of left ventricular structures in normotensive and hypertensive subjects by two-dimensional echocardiography: Anthropometric correlates in hypertension Mr. Ugwu Anthony Chukwuka * MSc, Mr. Okwor

More information

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? O R I G I N A L A R T I C L E Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? H. Borsboom 1#, L. Smans 1#, M.J.M.

More information

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN

More information

Congestive Heart Failure in Renal Transplant Recipients: Risk Factors, Outcomes, and Relationship with Ischemic Heart Disease

Congestive Heart Failure in Renal Transplant Recipients: Risk Factors, Outcomes, and Relationship with Ischemic Heart Disease J Am Soc Nephrol 13: 1084 1090, 2002 Congestive Heart Failure in Renal Transplant Recipients: Risk Factors, Outcomes, and Relationship with Ischemic Heart Disease CLAUDIO RIGATTO,* ATRICK ARFREY, ROBERT

More information

Cardiovascular Diseases before and after Renal Transplantation

Cardiovascular Diseases before and after Renal Transplantation Med. J. Cairo Univ., Vol. 84, No. 1, June: 409-415, 2016 www.medicaljournalofcairouniversity.net Cardiovascular Diseases before and after Renal Transplantation TAREK H. EL-SHABONY, M.D.*; HUSSEIN M. HESHMATE,

More information

ANEMIA & HEMODIALYSIS

ANEMIA & HEMODIALYSIS ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.

More information

Changes in Left Atrial Size in Patients with Lone Atrial Fibrillation

Changes in Left Atrial Size in Patients with Lone Atrial Fibrillation Clin. Cardiol. 14,652-656 (1991) Changes in Left Atrial Size in Patients with Lone Atrial Fibrillation GUILLERMO SOSA SUAREZ, M.D., SIEVEN LAMPERT, M.D., F.A.C.C., SHMUEL RAVID, M.D., BERNARD LOWN, M.D.,

More information

Echocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease

Echocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease International Journal of Research in Medical Sciences Behera BK et al. Int J Res Med Sci. 2017 Nov;5(11):4783-4788 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20174672

More information

DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.

DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio

More information

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular

More information

Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease

Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease J Am Soc Nephrol 15: 1640 1647, 2004 Development, Prevention, and Potential Reversal of Left Ventricular Hypertrophy in Chronic Kidney Disease LAWRENCE P. MCMAHON,* SIMON D. ROGER, and ADEERA LEVIN, FOR

More information

LEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION

LEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION LEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION Objective: Chronic kidney disease (CKD) is a major cause of cardiovascular morbidity and mortality

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?

Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? (24) 18, S23 S28 & 24 Nature Publishing Group All rights reserved 95-92/4 $3. www.nature.com/jhh ORIGINAL ARTICLE Does the reduction in systolic blood pressure alone explain the regression of left ventricular

More information

Body Mass Index and Blood Pressure Influences on Left Ventricular Mass and Geometry in African Americans

Body Mass Index and Blood Pressure Influences on Left Ventricular Mass and Geometry in African Americans Body Mass Index and Blood Pressure Influences on Left Ventricular Mass and Geometry in African Americans The Atherosclerotic Risk In Communities (ARIC) Study Ervin Fox, Herman Taylor, Michael Andrew, Hui

More information

Left Ventricular Mass Forerunner of Future Cardiovascular Morbidity in Young Healthy Population?

Left Ventricular Mass Forerunner of Future Cardiovascular Morbidity in Young Healthy Population? ISPUB.COM The Internet Journal of Cardiology Volume 7 Number 2 Left Ventricular Mass Forerunner of Future Cardiovascular Morbidity in Young Healthy Population? S Mahajan, S Diwan, A Wanjari, S Acharya

More information

Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis

Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1689-1694, 2014 Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis XIAOZHAO LI 1,

More information

ORIGINAL ARTICLE. LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION Pooja Shashidharan 1

ORIGINAL ARTICLE. LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION Pooja Shashidharan 1 LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION Pooja Shashidharan 1 HOW TO CITE THIS ARTICLE: Pooja Shashidharan. Left ventricular mass index: a predictor

More information

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease (2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

End stage renal disease (ESRD) is the irreversible deterioration of renal function

End stage renal disease (ESRD) is the irreversible deterioration of renal function 28 Journal of the association of physicians of india JANUARY 2014 VOL. 62 Original Article Echocardiographic Assessment of Cardiac Dysfunction in Patients of End Stage Renal Disease on Haemodialysis Mukesh

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

Abody of evidence demonstrates that alcohol

Abody of evidence demonstrates that alcohol BRIEF COMMUNICATIONS AJH 1998;11:230 234 The Effects of Alcohol Consumption on Ambulatory Blood Pressure and Target Organs in Subjects With Borderline to Mild Hypertension Olga Vriz, Diana Piccolo, Enrico

More information

Interventricular Septum Thickness Predicts Future Systolic Hypertension in Young Healthy Pilots

Interventricular Septum Thickness Predicts Future Systolic Hypertension in Young Healthy Pilots 15 Original Article Hypertens Res Vol.31 (2008) No.1 p.15-20 Interventricular Septum Thickness Predicts Future Systolic Hypertension in Young Healthy Pilots Chagai GROSSMAN 1), Alon GROSSMAN 2), Nira KOREN-MORAG

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives

More information

Gender-Adjustment and Cutoff Values of Cornell Product in Hypertensive Japanese Patients

Gender-Adjustment and Cutoff Values of Cornell Product in Hypertensive Japanese Patients CLINICAL STUDY Gender-Adjustment and Cutoff Values of Cornell Product in Hypertensive Japanese Patients Joji Ishikawa, 1 MD, Yuko Yamanaka, 2 MD, Ayumi Toba, 1 MD, Shintaro Watanabe, 3 MD and Kazumasa

More information

Outcome and risk factors of ischemic heart disease in chronic uremia

Outcome and risk factors of ischemic heart disease in chronic uremia Kidney International, Vol. 49 (1996), pp. 1428 1434 Outcome and risk factors of ischemic heart disease in chronic uremia ATRICK S. ARFREY, ROBERT N. FOLEY, JOHN D. HARNETF, GLORIA M. KENT, DAVID MURRAY,

More information

A STUDY OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN HYPERTENSION Ravi Keerthy M 1

A STUDY OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN HYPERTENSION Ravi Keerthy M 1 A STUDY OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN HYPERTENSION Ravi Keerthy M 1 HOW TO CITE THIS ARTICLE: Ravi Keerthy M. A Study of Left Ventricular Diastolic Dysfunction in Hypertension. Journal of

More information

Report and Opinion 2016;8(12)

Report and Opinion 2016;8(12) Prevalence of calcific aortic valve stenosis in haemodialysis patients at AL Hussein University Hospital. Ahmed Alaa Saad 1, Sami H. Nooh 2, Osama A. Khamis 1, Magdy E. Mohamed 1, Mohamed Abdelhafez 1

More information

Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation

Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation Pediatr Transplantation 2004: 8: 249 254 Printed in UK. All rights reserved Copyright Ó 2004 Blackwell Munksgaard Pediatric Transplantation Echocardiographic changes and risk factors for left ventricular

More information

NATIONAL QUALITY FORUM Renal EM Submitted Measures

NATIONAL QUALITY FORUM Renal EM Submitted Measures NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB

More information

Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients

Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients ORIGINAL PAPER Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients Wenjin Liu, MD; Hong Ye, MD; Bing Tang, MD; Zhiping Sun, MD; Ping Wen, MD; Wenhui Wu, MD;

More information

Improvement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis

Improvement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of

More information

LEFT VENTRICULAR STRUCTURE AND SYSTOLIC FUNCTION IN AFRICAN AMERICANS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY

LEFT VENTRICULAR STRUCTURE AND SYSTOLIC FUNCTION IN AFRICAN AMERICANS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY LEFT VENTRICULAR STRUCTURE AND SYSTOLIC FUNCTION IN AFRICAN AMERICANS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY Objectives: To estimate prevalence of left ventricular (LV) hypertrophy and its

More information

Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension

Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension 525 Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension PHIMDA Kriangsak 1* and CHOTNOPARATPAT Paiboon 2 1 Diabetes and Hypertension Clinic,

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage

More information

HYPERTENSION AND HEART FAILURE

HYPERTENSION AND HEART FAILURE HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Prevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study

Prevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120

More information

On Referral to our Unit

On Referral to our Unit Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

Left Ventricular Hypertrophy Evaluation in Obese Hypertensive Patients. Effect of Left Ventricular Mass Index Criteria

Left Ventricular Hypertrophy Evaluation in Obese Hypertensive Patients. Effect of Left Ventricular Mass Index Criteria Original Article Left Ventricular Hypertrophy Evaluation in Obese Hypertensive Patients. Effect of Left Ventricular Mass Index Criteria Eduardo Cantoni Rosa, Valdir Ambrósio Moysés, Ricardo Cintra Sesso,

More information

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu

More information

ONLINE DATA SUPPLEMENT. Impact of Obstructive Sleep Apnea on Left Ventricular Mass and. Diastolic Function

ONLINE DATA SUPPLEMENT. Impact of Obstructive Sleep Apnea on Left Ventricular Mass and. Diastolic Function ONLINE DATA SUPPLEMENT Impact of Obstructive Sleep Apnea on Left Ventricular Mass and Diastolic Function Mitra Niroumand Raffael Kuperstein Zion Sasson Patrick J. Hanly St. Michael s Hospital University

More information

Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient

Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Dr. Peersab.M. Pinjar 1, Dr Praveenkumar Devarbahvi 1 and Dr Vasudeva Murthy.C.R 2, Dr.S.S.Bhat 1, Dr.Jayaraj S G 1

More information

Rotation: Echocardiography: Transthoracic Echocardiography (TTE)

Rotation: Echocardiography: Transthoracic Echocardiography (TTE) Rotation: Echocardiography: Transthoracic Echocardiography (TTE) Rotation Format and Responsibilities: Fellows rotate in the echocardiography laboratory in each clinical year. Rotations during the first

More information

Because of important technologic advances achieved over

Because of important technologic advances achieved over Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic

More information

ECHOCARDIOGRAPHY. Patient Care. Goals and Objectives PF EF MF LF Aspirational

ECHOCARDIOGRAPHY. Patient Care. Goals and Objectives PF EF MF LF Aspirational Patient Care Be able to: Perform and interpret basic TTE and X cardiac Doppler examinations Perform and interpret a comprehensive X TTE and cardiac Doppler examination Perform and interpret a comprehensive

More information

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives

Objectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

Correlation of Hypretensive Left Ventricular Hypertrophy with Renal End Organ Damage

Correlation of Hypretensive Left Ventricular Hypertrophy with Renal End Organ Damage ORIGINAL ARTICLE Correlation of Hypretensive Left Ventricular Hypertrophy with Renal End Organ Damage TANVIR AHMAD BHATTI 1, SYED MUHAMMAD AFTAB HASSAN SHAH 2, WASEEM ASHRAF 3, HAROON ASHRAF 4 ABSTRACT

More information

When should you treat blood pressure in the young?

When should you treat blood pressure in the young? ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department

More information

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized

More information

National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation

National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of

More information

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,

More information

A rationale for an individualized haemoglobin target

A rationale for an individualized haemoglobin target Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of

More information

(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)

(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) [1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120

More information

Preventing the cardiovascular complications of hypertension

Preventing the cardiovascular complications of hypertension European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Pulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis

Pulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis Dialysis Pulmonary Hypertension and Predisposing Factors in Patients Receiving Hemodialysis Seyed Alijavad Mousavi, 1 Mitra Mahdavi-Mazdeh, 2 Hooman Yahyazadeh, 1 Mitra Azadi, 3 Nahid Rahimzadeh, 4 Hajar

More information

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August

More information

Distribution of Cardiac Geometric Patterns on Echocardiography in Essential Hypertension. Impact of Two Criteria of Stratification

Distribution of Cardiac Geometric Patterns on Echocardiography in Essential Hypertension. Impact of Two Criteria of Stratification Original Article Distribution of Cardiac Geometric Patterns on Echocardiography in Essential Hypertension. Impact of Two Criteria of Stratification Eduardo Cantoni Rosa, Valdir Ambrósio Moisés, Ricardo

More information

Value of echocardiography in chronic dyspnea

Value of echocardiography in chronic dyspnea Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting

More information

How Low Do We Go? Update on Hypertension

How Low Do We Go? Update on Hypertension How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states

More information

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:

More information

Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function. Sex-Related Differences in the Framingham Heart Study

Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function. Sex-Related Differences in the Framingham Heart Study Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function Sex-Related Differences in the Framingham Heart Study Martin K. Rutter, MB, ChB; Helen Parise, ScD; Emelia J. Benjamin,

More information

Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians

Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve Prediction of Mortality in American Indians Combined Echocardiographic Left Ventricular Hypertrophy and Electrocardiographic ST Depression Improve rediction of Mortality in American Indians The Strong Heart Study eter M. Okin, Mary J. Roman, Elisa

More information

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto Introduction Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy,

More information

Hypertension and diabetic nephropathy

Hypertension and diabetic nephropathy Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney

More information

Patients with end-stage renal disease (ESRD), particularly

Patients with end-stage renal disease (ESRD), particularly Renal Transplantation Is Not Associated with Regression of Left Ventricular Hypertrophy: A Magnetic Resonance Study Rajan K. Patel,* Patrick B. Mark,* Nicola Johnston, Ellon McGregor, Henry J. Dargie,

More information

Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension

Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension Pediatr Cardiol (2014) 35:622 626 DOI 10.1007/s00246-013-0829-7 ORIGINAL ARTICLE Concordance of Measures of Left-Ventricular Hypertrophy in Pediatric Hypertension D. Mirchandani J. Bhatia D. Leisman E.

More information

Cardiovascular disease is highly prevalent at all stages of

Cardiovascular disease is highly prevalent at all stages of Anemia and the Heart in Chronic Kidney Disease Nadia Zalunardo* and Adeera Levin Cardiovascular disease is highly prevalent at all stages of chronic kidney disease (CKD) and is the leading cause of morbidity

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

The Framingham Heart Study has recently

The Framingham Heart Study has recently AJH 1997;10:836 842 Influence of Nighttime Blood Pressure on Left Atrial Size in Uncomplicated Arterial Systemic Hypertension Maurizio Galderisi, Antonio Petrocelli, Ayman Fakher, Annibale Izzo, Alfonso

More information